Sun Pharma the latest to recall metformin after carcinogen tests come up positive - FiercePharma
Once cleared by the FDA of a probable carcinogen, generic diabetes med metformin has now been the target of a growing number of recalls. This week, a seventh drugmaker has joined the metformin recall parade after finding high levels of a potential cancer-causing contaminant.
Sun Pharma recalled one lot of its Riomet ER, an extended-release version of the common diabetes med, after testing showed high levels of N-nitrosodimethylamine (NDMA), the drugmaker said Wednesday.
The recalled lot contains 747 bottles of the drug with an expiration date of October 2021, Sun said in a release.
Infographic Download
Reducing Time to Clinic for Your Biomedical Applications
Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.
Download today and learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.
Sun is now the seventh drugmaker to launch voluntary recalls of their versions of metformin after the FDA earlier this year found high levels of NDMA, a contaminant connected to global recalls of "sartan"-based heart pressure drugs and heartburn med Zantac, in tested lots.
0 Response to "Sun Pharma the latest to recall metformin after carcinogen tests come up positive - FiercePharma"
Post a Comment